Trials / Completed
CompletedNCT03437837
Validation of the CPS+EG, Neo-Bioscore and Modified Neo-Bioscore Staging Systems After PST of BC in China
Validation of CPS+EG, Neo-Bioscore and Modified Neo-Bioscore Staging System After Preoperative Systemic Therapy of Breast Cancer in Multi-center in China
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,077 (actual)
- Sponsor
- Peking University First Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Prognostic assessment after preoperative systemic therapy (PST) plays a vital role in breast cancer patients. The clinical-pathologic staging system incorporating estrogen receptor (ER)-negative disease and nuclear grade 3 tumor pathology (CPS+EG staging system) can effectively predict prognosis after PST. The Neo-Bioscore has been developed by the incorporation of the human epidermal growth factor receptor 2 (HER2) status into the CPS+EG staging system. But in a real world in China, the both staging systems had limits because of trastuzumab administration varied a lot in China from the United States. This retrospective study will validate CPS+EG and Neo-Bioscore system and explored a modified Neo-Bioscore system in multiple centers.
Conditions
- Breast Cancer
- Neoadjuvant Therapy
- Neoplasm Staging
- Estrogen Receptor
- Histological Grade
- HER2
- Prognosis
- Predictive Value of Tests
Timeline
- Start date
- 2017-05-01
- Primary completion
- 2018-09-29
- Completion
- 2018-09-29
- First posted
- 2018-02-19
- Last updated
- 2020-09-28
Locations
12 sites across 1 country: China
Source: ClinicalTrials.gov record NCT03437837. Inclusion in this directory is not an endorsement.